RxDoctor Payments Data

James Milhollin, MD

Internal Medicine · Lenoir City, TNNPI 1457438525

Payments from drug & device makers

$1,107in general payments, 2019–2025

Across 60 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$250
  • Amgen$172
  • GSK$108
  • Pfizer$105
  • AbbVie$97
  • Novo Nordisk$90
  • plus $286 from 10 others

What the payments were for

  • Food & beverage$94786%
  • Education$16014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,107 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$125,038
Medicare patients
432
Services billed
2,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban266$268,458
OzempicSemaglutide114$137,835
FarxigaDapagliflozin Propanediol116$116,545
JardianceEmpagliflozin109$106,858
XareltoRivaroxaban58$61,005
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$42,774
RybelsusSemaglutide41$42,729
Tresiba Flextouch U-200Insulin Degludec46$40,692
MyrbetriqMirabegron47$38,747
MounjaroTirzepatide24$32,398
CreonLipase/Protease/Amylase13$31,268
JanuviaSitagliptin Phosphate24$29,987
Repatha SureclickEvolocumab36$29,461
LinzessLinaclotide36$24,345
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$12,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$105$276,044288 claims
Novo NordiskOzempic, Rybelsus$90$180,563155 claims
AstraZenecaFarxiga, Symbicort$79$124,205128 claims
Boehringer IngelheimJardiance$19$106,858109 claims
Johnson & JohnsonXarelto$16$61,00558 claims
AbbVieCreon, Linzess, Synthroid$97$59,37399 claims
GSKTrelegy Ellipta, Breo Ellipta$108$54,39475 claims
Astellas Pharma US IncMyrbetriq$250$38,74747 claims
Lilly USA, LLCMounjaro$49$32,39824 claims
MerckJanuvia$12$29,98724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Lenoir City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →